Market Watch: WHO and the African Medicines Agency signed a reliance framework

What changed. WHO and the African Medicines Agency signed a formal collaboration framework on 21 May 2026, at the Seventy-ninth World Health Assembly, to drive regulatory harmonisation, convergence and reliance across the continent and to operationalise the AMA as a working institution.¹

Joint operational plans run three to five years. The framework builds on the African Union and WHO memorandum of understanding signed in May 2025.

The corroborating signal. The European Medicines Agency's Management Board, meeting on 10 and 11 June 2026, reported that a three-way memorandum between the AMA, the Commission's health directorate and EMA was nearing completion, with joint training for Francophone regulators scheduled for October 2026.²

Two of the largest regulatory systems in the world are building formal channels into the same continental body, in the same quarter.

Why it matters. Africa has been planned, by nearly everyone, as fifteen or twenty separate national dossiers. That assumption is the reason most companies either enter a handful of markets or none. A functioning continental reliance route changes the arithmetic of the whole region, and the companies that notice early get the uncontested years.

The honest caveat. A signed framework is not an operating pathway. What exists today is an agreement to build one, with operational plans measured in years. No company should re-sequence Africa this quarter on the strength of it.

What to do now. Stop building African dossiers as unrelated national packages by default. Build one reliance-ready dossier keyed to a WHO-listed authority or an EMA reference approval, because that is the input both routes will want. Then track which national authorities begin accepting AMA-routed opinions, and budget for a transitional period in which both routes run in parallel rather than one replacing the other.

The transition is where the cost sits. It usually is.